Abstract
Purpose :
Ocular sarcoidosis is a chronic inflammatory disease that affetcts the eye. Uveitis is the most common symptom, affecting 85-95% of patients with ocular sarcoidosis. It presents with characteristic granulomatous uveitis findings, and the visual prognosis is generally good. However, the long-term prognosis of ocular sarcoidosis with uveitis is not well understood. In this study, we investigated the visual prognosis of ocular sarcoidosis patients with more than 5 years of follow-up, and the associated ocular and systemic findings.
Methods :
We retrospectively investigated the medical records of 36 ocular sarcoidosis patients with uveitis who had been followed up for more than 5 years at National Defense Medical College. Patient demographics, visual acuity (VA) and intraocular pressure (IOP) at the first and last visit, and the ocular findings, treatment, and complications during the clinical course were reviewed.
Results :
The mean patient age was 60.1 ± 13.4 years, with a male-to-female ratio of 8:28. The mean follow-up period was 108 ± 30 months. Mean logMAR VA decreased from 0.22 ± 0.35 at the first visit to 0.14 ± 0.32 at the last visit, but was not significant. At the last visit, 16 of the patients (44.4%) had visual acuity of 1.0 or better, 12 patients (33.3%) had visual acuity of 0.5 to 1.0, 8 patients (22.2%) had visual acuity of 0.1 to 0.5, and none had visual acuity of 0.1 or less. Patients with optic disc hyperfluorescence on fluorescein angiography (-0.08 ± 0.11 vs. 0.16 ± 0.31, P = 0.02), cystoid macular edema（CME） (0.03± 0.22 vs. 0.28 ± 0.37, P = 0.02), and vitrectomy (0.03 ± 0.28 vs. 0.29 ± 0.32, P < 0.005) had significantly worse visual acuity at the final visit.
Conclusions :
This study indicated that the visual prognosis of ocular sarcoidosis with uveitis is generally preferable after 5 years of onset, but is significantly worse in patients with optic disc inflammation or CME, and in those who underwent vitrectomy.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.